January 1, 2026 – Patient Worthy

Renalys Pharma Announces Positive Phase III Results for Sparsentan in Japanese IgA Nephropathy Patients

Post author:Austin Newman
Post published:January 1, 2026
Post category:IgA Nephropathy

As reported on PharmaBiz, Renalys Pharma has reported encouraging topline data from its Phase III trial evaluating sparsentan (RE-021), an oral dual endothelin and angiotensin II receptor antagonist, in Japanese…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More